Recursion Pharmaceuticals (RXRX) Interest Expenses (2020 - 2026)

Recursion Pharmaceuticals' Interest Expenses history runs 7 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• Quarterly Interest Expenses fell 18.02% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.7 million (up 37.99% YoY) and the FY2025 annual result came in at $665.4 million, up 42.74% from the prior year.
• Interest Expenses was $4.3 million for Q1 2026 at Recursion Pharmaceuticals, up from $4.0 million in the prior quarter.
• Across five years, Interest Expenses topped out at $25.8 million in Q2 2025 and bottomed at $13000.0 in Q3 2022.
• A 5-year average of $5.4 million and a median of $3.6 million in 2022 frame the typical range for Interest Expenses.
• Peak annual rise in Interest Expenses reached 23620.0% in 2022, while the deepest fall reached 99.44% in 2022.
• Recursion Pharmaceuticals' Interest Expenses stood at $3.6 million in 2022, then surged by 175.18% to $9.8 million in 2023, then jumped by 34.08% to $13.1 million in 2024, then plunged by 69.69% to $4.0 million in 2025, then rose by 8.47% to $4.3 million in 2026.
• Business Quant data shows RXRX's Interest Expenses at $4.3 million in Q1 2026, $4.0 million in Q4 2025, and $20.2 million in Q3 2025.